Health1 min read

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

By · Via STAT Health · Published by Everything Blog

In short

The Food and Drug Administration announced on Friday that it rejected Capricor Therapeutics' deramiocel for patients with Duchenne muscular dystrophy. Designed for patients who have already lost the ability to walk, the cell therapy aimed to address a critical therapeutic void. However, the candidate failed in two randomized clinical trials to preserve arm muscle function or stave off heart failure. Consequently, the agency declined to allow the therapy onto the market despite the pressing need for effective interventions.

Key points

  • Regulating interventions for progressive muscle-wasting conditions remains a persistent c…: Regulating interventions for progressive muscle-wasting conditions remains a persistent challenge for the Food and Drug Administration.
  • The regulatory decision halts the commercial path for a treatment targeting patients with…: The regulatory decision halts the commercial path for a treatment targeting patients with highly limited therapeutic options.
  • Clinical failure across two randomized studies directly led to the agency's decision to d…: Clinical failure across two randomized studies directly led to the agency's decision to deny commercial market entry.

Sources checked by our analysis pipeline: 1

The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms.

But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health